Rett Syndrome Phase I/II trial shows significant benefits
Filed with ASX · · 8 pages · English
Neurotech International Ltd. on 6ix
In the deck
Story so far
Earlier from Neurotech International
- Neurotech Completes $10 Million Capital Raise
- Positive Top-Line Rett Syndrome Clinical Trial Results
- Phase II/III ASD Trial Successfully Meets Primary Endpoint
- Last Patient Completes Treatment in NTIASD2 Clinical Trial
- Rett Syndrome Patients to Receive NTI164 for 52 Weeks
Later from Neurotech International
- Further clinical benefit at 52 weeks in PANDAS/PANS patients
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
- Significant improvement in Autism patients at 12 weeks
- Phase II/III autism trial shows further benefits
- Further Significant Improvement in Rett Syndrome Patients
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International